AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
113_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
Introduction_NOMZ
and_PHC
liabilities_NOMZ
of_PIN
Astra_NN
was_VBD [PASS]
recorded_VBN
as_IN
On_PIN
disposal_NN
of_PIN
a_DT
business_NOMZ
,_,
the_DT
gain_NN
or_CC
loss_NN
The_DT
accompanying_VBG
consolidated_JJ
Financial_NN
goodwill_NN
._.
The_DT
amount_NN
allocated_VBN [WZPAST]
to_PIN
in-process_JJ
under_IN
US_FPP1
GAAP_NN
may_POMD
differ_VB
from_PIN
that_DEMO
under_IN
Statements_NOMZ
included_VBD
in_PIN
this_DEMO
Annual_JJ
Report_NN
research_NN
and_PHC
development_NOMZ
was_VBD
,_,
as_IN
required_VBN [SUAV]
UK_NN
GAAP_NN
due_JJ
principally_RB
to_PIN
goodwill_NN
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
by_PIN
US_FPP1
GAAP_NN
,_,
expensed_VBD
immediately_TIME
in_PIN
the_DT
capitalized_JJ
and_PHC
amortised_JJ
,_,
together_RB
with_PIN
the_DT
There_EX
are_VPRT
certain_JJ
significant_JJ
differences_NN
first_RB
reporting_VBG [PUBV]
period_NN
after_IN
the_DT
business_NOMZ
appropriate_JJ
share_NN
of_PIN
other_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
which_WDT [WHOBJ]
combination_NOMZ
._.
Fair_NN
value_NN
adjustments_NOMZ
to_PIN
the_DT
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
affect_VPRT
AstraZenecas_NN
net_JJ
income_NN
and_CC
recorded_VBN
amount_NN
of_PIN
inventory_NN
were_VBD [PASS]
recognized_VBN [PRIV]
previously_TIME
._.
shareholders_NN
equity_NOMZ
and_CC
,_,
on_PIN
pages_NN
113_CD
to_TO
expensed_VBN
in_PIN
the_DT
period_NN
the_DT
inventory_NN
was_VBD [BEMA]
123_CD
,_,
additional_JJ
information_NOMZ
under_IN
US_FPP1
GAAP_NN
utilised_VBD
._.
Additional_JJ
amortisation_NOMZ
and_PHC
Capitalisation_NOMZ
of_PIN
interest_NN
is_VPRT [PASS]
set_VBN
out_PIN
as_IN
follows_VPRT
:_:
depreciation_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
recorded_VBN
in_PIN
AstraZeneca_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
in_PIN
its_PIT
respect_NN
of_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
to_PIN
UK_NN
GAAP_NN
Financial_NN
Statements_NOMZ
._.
US_FPP1
GAAP_NN
summary_NN
of_PIN
differences_NN
between_PIN
UK_NN
tangible_JJ
and_PHC
intangible_JJ
assets_NN
and_CC
the_DT
requires_VPRT [SUAV] [THATD]
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
and_PHC
US_FPP1
GAAP_NN
accounting_GER
principles_NN
:_:
resulting_VBG
goodwill_NN
._.
of_PIN
constructing_VBG
fixed_JJ
assets_NN
to_TO
be_VB [PASS]
capitalized_VBN
page_NN
113_CD
and_CC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
In_PIN
the_DT
consolidated_JJ
Financial_NN
Statements_NOMZ
net_JJ
income_NN
:_:
page_NN
116_CD
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
Dividends_NN
on_PIN
acquisitions_NOMZ
made_VBN [WZPAST]
prior_RB
to_PIN
1_CD
January_NN
1998_CD
Under_IN
UK_NN
GAAP_NN
,_,
Ordinary_NN
Share_NN
dividends_NN
US_FPP1
GAAP_NN
condensed_JJ
consolidated_JJ
accounted_VBN
for_PIN
under_IN
the_DT
purchase_NN
method_NN
proposed_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
year_NN
in_PIN
statement_NOMZ
of_PIN
operations_NOMZ
:_:
page_NN
117_CD
has_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
against_PIN
shareholders_NN
respect_NN
of_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
recommended_VBN [SUAV]
by_PIN
equity_NOMZ
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
UK_NN
the_DT
Board_NN
of_PIN
Directors_NN
for_PIN
approval_NN
by_PIN
the_DT
US_FPP1
GAAP_NN
statement_NOMZ
of_PIN
comprehensive_JJ
Financial_NN
Reporting_GER
Standard_NN
10_CD
Goodwill_NN
shareholders_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
income_NN
:_:
page_NN
117_CD
and_CC
Intangible_NN
Assets_NN
,_,
goodwill_NN
on_PIN
dividends_NN
are_VPRT [PASS]
not_XX0
provided_VBN
for_PIN
until_IN
declared_VBN [PUBV] [THATD]
acquisitions_NOMZ
made_VBN
after_IN
1_CD
January_NN
1998_CD
is_VPRT [BEMA]
by_PIN
the_DT
Board_NN
._.
stock_NN
compensation_NOMZ
:_:
page_NN
118_CD
capitalized_VBN
and_PHC
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
which_WDT [WHSUB]
is_VPRT [SPAU] [PASS]
generally_RB
presumed_VBN [PRIV]
not_XX0
to_PIN
Deferred_JJ
taxation_NOMZ
pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
:_:
exceed_VB
20_CD
years_NN
._.
UK_NN
GAAP_NN
requires_VPRT [SUAV]
that_THVC
on_PIN
Deferred_JJ
taxation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
full_JJ
liability_NOMZ
page_NN
119_CD
subsequent_JJ
disposal_NN
or_CC
termination_NOMZ
of_PIN
a_DT
basis_NN
under_IN
US_FPP1
GAAP_NN
,_,
which_WDT [SERE]
permits_VPRT
previously_TIME
acquired_VBN
business_NOMZ
,_,
any_QUAN
goodwill_NN
deferred_VBN
tax_NN
assets_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
if_COND
their_TPP3
taxation_NOMZ
:_:
page_NN
121_CD
previously_TIME
taken_VBN
directly_RB
to_PIN
shareholders_NN
realisation_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
more_EMPH
likely_JJ
equity_NOMZ
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
in_PIN
the_DT
income_NN
than_PIN
not_XX0
._.
Under_IN
current_JJ
UK_NN
GAAP_NN
,_,
full_JJ
shareholders_NN
equity_NOMZ
:_:
page_NN
122_CD
statement_NOMZ
against_PIN
the_DT
profit_NN
or_CC
loss_NN
on_PIN
provision_NN
is_VPRT [SPAU] [PASS]
also_RB
made_VBN
although_CONC
there_EX
are_VPRT
a_DT
disposal_NN
or_CC
termination_NOMZ
._.
Up_IN
until_IN
1_CD
January_NN
number_NN
of_PIN
different_JJ
bases_NN
on_PIN
which_WDT [PIRE]
this_DEMP
acquired_VBN
intangible_JJ
assets_NN
and_PHC
goodwill_NN
:_:
2002_CD
,_,
under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
was_VBD
calculation_NOMZ
is_VPRT [PASS]
made_VBN
,_,
for_CONJ
example_NULL
rolled_VBD
over_IN
page_NN
122_CD
required_VBN [SUAV]
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
._.
Now_DPAR
,_,
instead_CONJ
of_NULL
being_VBG [WZPRES] [PASS]
amortised_VBN
,_,
goodwill_NN
is_VPRT
US_FPP1
GAAP_NN
condensed_JJ
consolidated_JJ
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
Amortisation_NOMZ
Pension_NN
and_CC
post-retirement_JJ
benefits_NN
statement_NOMZ
of_PIN
cash_NN
flows_NN
:_:
page_NN
123_CD
charged_VBN
under_IN
UK_NN
GAAP_NN
is_VPRT [PASS]
added_VBN [PUBV]
back_RB
in_PIN
There_EX
are_VPRT
four_CD
main_JJ
differences_NN
between_PIN
the_DT
reconciliation_NOMZ
of_PIN
net_JJ
income_NN
._.
The_DT
current_JJ
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
in_PIN
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
intangible_JJ
recognized_VBN [PRIV]
as_IN
assembled_VBN
accounting_GER
for_PIN
pension_NN
costs_NN
:_:
accounting_GER
principles_NN
workforce_NN
has_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
as_IN
goodwill_NN
._.
i_FPP1
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
measurements_NOMZ
of_PIN
Purchase_NN
accounting_GER
adjustments_NOMZ
Identifiable_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
plan_VPRT
assets_NN
and_PHC
obligations_NOMZ
to_TO
be_VB [PASS]
made_VBN
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
merger_NN
of_PIN
Astra_NN
and_CC
principally_RB
include_VPRT
patents_NN
,_,
know-how_NN
and_CC
as_RB
at_PIN
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
Zeneca_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
of_PIN
product_NN
registrations_NOMZ
,_,
are_VPRT [PASS]
amortised_VBN
over_IN
or_CC
a_DT
date_NN
not_XX0
more_EMPH
than_PIN
three_CD
months_NN
equals_VPRT
pooling-of-interests_NN
._.
Under_IN
US_FPP1
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
which_WDT [WHSUB]
vary_VPRT
prior_RB
to_PIN
that_DEMO
date_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
GAAP_NN
the_DT
merger_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
the_DT
between_PIN
five_CD
years_NN
and_CC
20_CD
years_NN
with_PIN
a_DT
calculations_NOMZ
may_POMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
results_NN
acquisition_NOMZ
of_PIN
Astra_NN
by_PIN
Zeneca_NN
using_VBG [WZPRES]
weighted_JJ
average_JJ
life_NN
of_PIN
approximately_RB
13_CD
of_PIN
the_DT
latest_JJ
actuarial_JJ
valuation_NOMZ
:_:
purchase_NN
accounting_GER
._.
accounting_GER
,_,
the_DT
cost_NN
of_PIN
the_DT
investment_NOMZ
is_VPRT
ii_FW
US_FPP1
GAAP_NN
mandates_VPRT
a_DT
particular_JJ
calculated_VBN [PRIV]
at_PIN
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
At_PIN
31_CD
December_NN
2003_CD
and_CC
2002_CD
,_,
actuarial_JJ
method_NN
the_DT
projected_VBN
unit_NN
issued_VBN [WZPAST]
together_RB
with_PIN
other_JJ
incidental_JJ
costs_NN
shareholders_NN
equity_NOMZ
includes_VPRT
capitalized_JJ
credit_NN
method_NN
and_CC
requires_VPRT [SUAV]
that_THVC
each_QUAN
and_CC
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
acquired_VBN
goodwill_NN
of_PIN
$_$
15,306_CD
m_NN
and_CC
$_$
13,647_CD
m_NN [BEMA]
significant_JJ
assumption_NOMZ
necessary_JJ
to_PIN
entity_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
fair_JJ
value_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
respectively_RB
net_JJ
of_PIN
amortisation_NOMZ
and_CC
determine_VB [SUAV] [PRIV]
annual_JJ
pension_NN
costs_NN
reflects_VPRT [PRIV]
the_DT
fair_JJ
value_NN
exercise_NN
,_,
increases_NN
in_PIN
the_DT
values_NN
impairment_NOMZ
of_PIN
$_$
2,596_CD
m_NN
and_CC
$_$
2,314_CD
m_NN
and_CC
best_JJ
estimates_NN
solely_RB
with_PIN
regard_NN
to_PIN
that_DEMO
of_PIN
Astras_NN
tangible_JJ
fixed_VBN
assets_NN
and_PHC
inventory_NN
capitalized_JJ
identifiable_JJ
intangible_JJ
assets_NN
of_PIN
individual_JJ
assumption_NOMZ
._.
UK_NN
GAAP_NN
does_EMPH
were_VBD [PASS]
recognized_VBN [PRIV]
and_PHC
values_VPRT
attributed_VBN
to_TO
$_$
9,536_CD
m_NN
and_CC
$_$
9,526_CD
m_NN [BEMA]
respectively_RB
net_PRED
of_PIN
not_XX0
mandate_VB
a_DT
particular_JJ
method_NN
,_,
but_CC
their_TPP3
in-process_JJ
research_NN
and_PHC
development_NOMZ
,_,
amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
$_$
6,739_CD
m_NN
requires_VPRT [SUAV]
that_THVC
the_DT
method_NN
and_CC
existing_VBG
products_NN
and_CC
assembled_VBN
workforce_NN
,_,
and_ANDC
$_$
4,807_CD
m._FW
Goodwill_NN
on_PIN
businesses_NOMZ
assumptions_NOMZ
taken_VBN
as_IN
a_DT
whole_JJ
should_NEMD
be_VB [BEMA]
together_RB
with_PIN
appropriate_JJ
deferred_VBN
taxation_NOMZ
disposed_VBN [WZPAST]
of_PIN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
gain_NN
or_CC
loss_NN
on_PIN
compatible_JJ
and_PHC
lead_JJ
to_PIN
the_DT
actuarys_NN
best_JJ
effects_NN
._.
The_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
disposal_NN
._.
estimate_NN
of_PIN
the_DT
cost_NN
of_PIN
providing_VBG
the_DT
investment_NOMZ
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
benefits_NN
promised_VBD [PUBV]
:_:
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
114_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
Derivative_NN
instruments_NOMZ
and_CC
hedging_VBG
d_SYM
tax_NN
paid_VBN
:_:
e_LS
capital_NN
expenditure_NN
and_PHC
accounting_GER
principles_NN
continued_VBD
activities_NOMZ
financial_JJ
investment_NOMZ
:_:
f_LS
acquisitions_NOMZ
and_CC
Under_IN
US_FPP1
GAAP_NN
,_,
all_QUAN
derivative_JJ
instruments_NOMZ
disposals_NN
:_:
g_VB
dividends_NN
paid_VBN [WZPAST]
to_PIN
shareholders_NN
:_:
iii_FW
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
negative_JJ
pension_NN
cost_NN
should_NEMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
assets_NN
or_CC
liabilities_NOMZ
in_PIN
h_JJ
management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
and_ANDC
may_POMD
arise_VB
where_RB
a_DT
significant_JJ
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
._.
SFAS_NN
95_CD
requires_VPRT [SUAV]
only_DWNT
three_CD
unrecognised_JJ
net_JJ
asset_NN
or_CC
gain_NN
exists_VPRT
at_PIN
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
net_JJ
income_NN
unless_COND
categories_NN
of_PIN
cash_NN
flow_NN
activity_NOMZ
being_VBG [WZPRES] [BEMA]
the_DT
time_NN
of_PIN
implementation_NOMZ
._.
This_DEMP
is_VPRT [BEMA]
they_TPP3
are_VPRT [PASS]
regarded_VBN
as_IN
hedges_NN
._.
Under_IN
UK_NN
a_DT
operating_GER
:_:
b_NN
investing_GER
:_:
and_ANDC
c_NN
financing_GER
._.
required_VBN [SUAV]
to_TO
be_VB [PASS]
amortised_VBN
on_PIN
a_DT
straightGAAP_NN
,_,
these_DEMO
instruments_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
line_NN
basis_NN
over_IN
the_DT
average_JJ
remaining_VBG
cost_NN
and_PHC
gains_NN
or_CC
losses_NN
deferred_VBN
until_IN
the_DT
Cash_NN
flows_VPRT
from_PIN
taxation_NOMZ
,_,
returns_NN
on_PIN
service_NN
period_NN
of_PIN
employees_NN
._.
Under_IN
UK_NN
underlying_VBG [WZPRES]
transactions_NOMZ
occur_VPRT
._.
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
and_PHC
GAAP_NN
,_,
AstraZenecas_NN
policy_NN
is_VPRT [BEMA]
not_XX0
to_PIN
dividends_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
ventures_NN
and_CC
recognize_VB [PRIV]
pension_NN
credits_NN
in_PIN
its_PIT
Financial_JJ
Deferred_JJ
income_NN
associates_NN
under_IN
FRS_NN
1_CD
would_PRMD
be_VB [PASS]
included_VBN
Statements_NOMZ
unless_COND
a_DT
refund_NN
of_PIN [STPR]
,_,
or_CC
Under_IN
UK_NN
GAAP_NN
,_,
profits_NN
or_CC
losses_NN
from_PIN
the_DT
as_RB
operating_VBG
activities_NOMZ
under_IN
SFAS_NN
95_CD
:_:
capital_NN
reduction_NOMZ
in_PIN [STPR]
,_,
contributions_NOMZ
is_VPRT [BEMA]
likely_PRED
:_:
and_ANDC
sale_NN
of_PIN
product_NN
related_VBN
intangible_JJ
assets_NN
are_VPRT
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
and_CC
generally_RB
taken_VBN
to_PIN
other_JJ
operating_GER
income_NN
at_PIN
acquisitions_NOMZ
and_PHC
disposals_NN
would_PRMD
be_VB [PASS]
iv_VBN
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
minimum_JJ
pension_NN
disposal_NN
and_CC
are_VPRT [PASS]
stated_VBN [PUBV]
after_IN
taking_VBG
account_NN
included_VBD
as_IN
investing_VBG
activities_NOMZ
:_:
and_ANDC
liability_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
through_PIN
other_JJ
of_PIN
product_NN
disposal_NN
costs_NN
and_PHC
costs_NN
of_PIN
minor_JJ
distributions_NOMZ
would_PRMD
be_VB [PASS]
included_VBN
as_IN
a_DT
comprehensive_JJ
income_NN
in_PIN
certain_JJ
outstanding_JJ
obligations_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
financing_GER
activity_NOMZ
under_IN
SFAS_NN
95_CD
._.
Under_IN
circumstances_NN
when_RB
there_EX
is_VPRT
a_DT
deficit_NN
of_PIN
such_JJ
profits_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
FRS_NN
1_CD
cash_NN
comprises_VPRT
cash_NN
in_PIN
hand_NN
and_PHC
plan_NN
assets_NN
relative_JJ
to_PIN
the_DT
accumulated_VBN
the_DT
income_NN
statement_NOMZ
in_PIN
subsequent_JJ
periods_NN
deposits_NN
repayable_JJ
on_PIN
demand_NN
,_,
less_JJ
benefits_NN
obligation_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
until_IN
all_QUAN
disposal_NN
obligations_NOMZ
and_PHC
overdrafts_NN
repayable_JJ
on_PIN
demand_NN
:_:
and_ANDC
liquid_JJ
there_EX
is_VPRT
no_SYNE
such_JJ
requirement_NOMZ
._.
resources_NN
comprise_VPRT
current_JJ
asset_NN
investments_NOMZ
held_VBD [PRIV]
as_IN
readily_RB
disposable_JJ
stores_NN
Restructuring_VBG [WZPRES]
costs_NN
Current_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
value_NN
._.
Under_IN
SFAS_NN
95_CD
cash_NN
equivalents_NN
,_,
Under_IN
UK_NN
GAAP_NN
,_,
provisions_NN
are_VPRT [PASS]
made_VBN
for_PIN
In_PIN
the_DT
Groups_NN
Financial_NN
Statements_NOMZ
prepared_VBD
comprising_VBG
short_JJ
term_NN
highly_AMP
liquid_JJ
restructuring_GER
costs_NN
once_TIME
a_DT
detailed_JJ
formal_JJ
plan_NN
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
cost_NN
is_VPRT [PASS]
accrued_VBN
for_PIN
the_DT
investments_NOMZ
,_,
generally_RB
with_PIN
original_JJ
maturities_NOMZ
is_VPRT [BEMA]
in_PIN
place_NN
and_CC
valid_JJ
expectations_NOMZ
have_VPRT [PEAS]
been_VBN
share_NN
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
employees_NN
under_IN
of_PIN
three_CD
months_NN
or_CC
less_JJ
,_,
are_VPRT [PASS]
grouped_VBN
together_RB
raised_VBN
in_PIN
those_DEMP
affected_VBN
that_DEMO
the_DT
restructuring_VBG
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
and_CC
the_DT
with_PIN
cash_NN
:_:
short_JJ
term_NN
borrowings_GER
repayable_JJ
will_PRMD
be_VB [PASS]
carried_VBN
out_PIN [STPR]
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
a_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
on_PIN
demand_NN
would_PRMD
not_XX0
be_VB [PASS]
included_VBN
within_PIN
number_NN
of_PIN
specific_JJ
criteria_NN
to_TO
be_VB [PASS]
met_VBN
before_IN
Plan_NN
as_IN
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
cash_NN
and_PHC
cash_NN
equivalents_NN
and_PHC
movements_NOMZ
such_JJ
costs_NN
can_POMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
._.
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Under_IN
US_FPP1
on_PIN
those_DEMO
borrowings_GER
would_PRMD
be_VB [PASS]
included_VBN
in_PIN
Among_PIN
these_DEMP
are_VPRT [BEMA]
the_DT
requirements_NOMZ
that_TSUB
costs_VPRT
GAAP_NN
,_,
the_DT
cost_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
financing_GER
activities_NOMZ
._.
associated_VBN [PASTP]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
difference_NN
between_PIN
the_DT
option_NOMZ
price_NN
and_CC
the_DT
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
costs_NN
are_VPRT [PASS]
incurred_VBN
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
or_CC
,_,
for_PIN
New_NN
accounting_GER
standards_NN
rather_RB
than_PIN
at_PIN
the_DT
date_NN
of_PIN
commitment_NOMZ
to_PIN
an_DT
variable_JJ
plans_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
the_DT
reporting_GER
SFAS_NN
143_CD
Accounting_GER
for_PIN
Asset_NN
Retirement_NOMZ
exit_NN
or_CC
disposal_NN
plan_NN
._.
To_PIN
the_DT
extent_NN
that_DEMO
period_NN
until_IN
measurement_NOMZ
date_NN
._.
Under_IN
the_DT
Obligation_NOMZ
addresses_VPRT
the_DT
accounting_GER
and_PHC
restructuring_GER
costs_NN
are_VPRT [PASS]
related_VBN
to_PIN
the_DT
activities_NOMZ
requirements_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
25_CD
any_QUAN
reporting_GER
for_PIN
obligations_NOMZ
associated_VBN [WZPAST]
with_PIN
the_DT
of_PIN
the_DT
acquired_VBN
company_NN
,_,
US_FPP1
GAAP_NN
allows_VPRT [SUAV]
compensation_NOMZ
cost_NN
would_PRMD
be_VB [PASS]
amortised_VBN
over_IN
retirement_NOMZ
of_PIN
long-lived_JJ
assets_NN
and_CC
the_DT
them_TPP3
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
liability_NOMZ
upon_PIN
the_DT
period_NN
from_PIN
the_DT
date_NN
the_DT
options_NOMZ
are_VPRT [PASS]
associated_VBN
asset_NN
retirement_NOMZ
costs_NN
._.
granted_VBN [SUAV] [PASTP]
to_PIN
the_DT
date_NN
they_TPP3
are_VPRT [BEMA]
first_JJ
exercisable_JJ
._.
effective_JJ
for_PIN
accounting_GER
periods_NN
beginning_VBG [WZPRES]
on_PIN
Under_IN
US_FPP1
GAAP_NN
,_,
in_PIN
the_DT
net_JJ
income_NN
or_CC
after_IN
15_CD
June_NN
2002_CD
._.
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
Software_NN
costs_VPRT
reconciliation_NOMZ
,_,
the_DT
Group_NN
has_VPRT [PEAS]
adjusted_VBN
for_PIN
143_CD
did_VBD
not_XX0
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
Under_IN
UK_NN
GAAP_NN
,_,
AstraZeneca_NN
capitalises_VPRT
stock_NN
compensation_NOMZ
costs_NN
calculated_VBN [PRIV]
under_IN
results_NN
or_CC
net_JJ
assets_NN
of_PIN
AstraZeneca_NN
._.
certain_JJ
defined_VBN
software_NN
costs_NN
and_PHC
amortises_NN
APB_NN
Opinion_NN
No._NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
SFAS_NN
146_CD
Accounting_GER
for_PIN
Costs_NN
Associated_NN
software_NN
costs_NN
are_VPRT [SPAU] [PASS]
generally_RB
capitalized_VBN
and_CC
Statement_NOMZ
of_PIN
cash_NN
flows_NN
:_:
Basis_NN
of_PIN
with_PIN
Exit_NN
or_CC
Disposal_NN
Activities_NOMZ
,_,
issued_VBN [PASTP]
on_PIN
30_CD
amortised_VBN
over_IN
three_CD
to_PIN
five_CD
years_NN
._.
preparation_NOMZ
July_NN
2002_CD
,_,
requires_VPRT [SUAV] [THATD]
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
AstraZenecas_NN
statement_NOMZ
of_PIN
Group_NN
cash_NN
flow_NN
or_CC
disposal_NN
activities_NOMZ
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
Foreign_NN
exchange_NN
is_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
Financial_NN
the_DT
costs_NN
are_VPRT [PASS]
incurred_VBN
rather_RB
than_PIN
at_PIN
the_DT
date_NN
Under_IN
UK_NN
GAAP_NN
,_,
unrealised_JJ
gains_NN
and_PHC
losses_NN
Reporting_GER
Standard_NN
1_CD
Revised_VBN
1996_CD
FRS_NN
of_PIN
commitment_NOMZ
to_PIN
an_DT
exit_NN
or_CC
disposal_NN
plan_NN
._.
on_PIN
foreign_JJ
currency_NN
transactions_NOMZ
to_TO
hedge_VB
1_CD
,_,
whose_WPS
objective_NN
and_PHC
principles_NN
are_VPRT [BEMA]
similar_PRED
The_DT
provisions_NN
are_VPRT [BEMA]
effective_PRED
for_PIN
disposals_NN
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
foreign_JJ
to_PIN
those_DEMP
set_VBN
out_PIN
in_PIN
SFAS_NN
95_CD
,_,
Statement_NOMZ
of_PIN
initiated_VBN
after_IN
31_CD
December_NN
2002_CD
and_CC
currency_NN
transactions_NOMZ
may_POMD
be_VB [PASS]
deferred_VBN
and_CC
Cash_NN
Flows_NN
._.
The_DT
principal_JJ
differences_NN
restatement_NOMZ
of_PIN
prior_JJ
periods_NN
is_VPRT [PASS]
not_XX0
required_VBN [SUAV]
._.
accounted_VBD
for_PIN
at_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
between_PIN
the_DT
standards_NN
relate_VPRT
to_PIN
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
146_CD
did_VBD
not_XX0
have_VB
a_DT
anticipated_JJ
transactions_NOMZ
._.
Under_IN
FRS_NN
1_CD
,_,
the_DT
Company_NN
material_NN
effect_NN
on_PIN
the_DT
results_NN
or_CC
net_JJ
assets_NN
of_PIN
such_JJ
deferral_JJ
is_VPRT [PASS]
not_XX0
permitted_VBN
except_PIN
in_PIN
presents_VPRT
its_PIT
cash_NN
flows_VPRT
for_PIN
a_DT
operating_GER
AstraZeneca_NN
and_CC
there_EX
was_VBD
no_SYNE
impact_NN
on_PIN
certain_JJ
defined_VBN
circumstances_NN
._.
activities_NOMZ
:_:
b_NN
dividends_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
prior_JJ
periods_NN
._.
ventures_NN
and_PHC
associates_NN
:_:
c_NN
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
115_CD
New_NN
accounting_GER
standards_NN
FIN_NN
No._NN
._.
46R_CD
Consolidation_NOMZ
of_PIN
Variable_JJ
continued_VBN
Interest_NN
Entities_NOMZ
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
address_VB
perceived_VBN [PRIV]
weaknesses_NOMZ
in_PIN
accounting_GER
for_PIN
SFAS_NN
No._NN
._.
148_CD
Accounting_GER
for_PIN
Stock_NN
Based_VBD
special_JJ
purpose_NN
or_CC
off-balance_JJ
sheet_NN
entities_NOMZ
Compensation_NOMZ
Transition_NOMZ
and_PHC
Disclosure_NN
and_CC
provides_VPRT
guidance_NN
on_PIN
identifying_VBG
the_DT
an_DT
Amendment_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
123_CD
party_NN
with_PIN
a_DT
controlling_VBG
financial_JJ
interest_NN
permits_VPRT
two_CD
additional_JJ
transition_NOMZ
methods_NN
for_PIN
resulting_VBG
from_PIN
arrangements_NOMZ
or_CC
financial_JJ
entities_NOMZ
that_TSUB
change_VPRT
from_PIN
the_DT
intrinsic_JJ
method_NN
interests_NN
as_IN
opposed_VBN
to_TO
voting_VBG [SUAV]
rights_NN
._.
If_COND
a_DT
to_PIN
the_DT
fair_JJ
value_NN
based_VBN
method_NN
of_PIN
accounting_VBG
party_NN
has_VPRT
a_DT
controlling_VBG
financial_JJ
interest_NN
in_PIN
a_DT
for_PIN
stock-based_JJ
employee_NN
compensation_NOMZ
._.
variable_JJ
interest_NN
entity_NOMZ
VIE_NN
then_RB
the_DT
assets_NN
,_,
The_DT
statement_NOMZ
also_RB
requires_VPRT [SUAV]
new_JJ
disclosures_NN
liabilities_NOMZ
and_PHC
results_NN
of_PIN
the_DT
VIE_NN
should_NEMD
be_VB
including_VBG
the_DT
ramp-up_JJ
effect_NN
of_PIN
adopting_VBG
fair_JJ
included_VBN
in_PIN
the_DT
consolidated_JJ
financial_JJ
value_NN
based_VBN
accounting_GER
for_PIN
stock-based_JJ
statements_NOMZ
of_PIN
the_DT
party_NN
._.
FIN46R_CD
applied_VBN
to_PIN
all_QUAN
employee_NN
compensation_NOMZ
on_PIN
reported_VBN [PUBV]
results_NN
VIEs_NN
or_CC
potential_JJ
VIEs_NN
referred_VBD
to_PIN
as_IN
special_JJ
and_CC
that_THVC
those_DEMO
effects_NN
be_VB [PASS]
disclosed_VBN [PUBV]
more_EMPH
purpose_NN
entities_NOMZ
for_PIN
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
prominently_RB
by_PIN
specifying_VBG
the_DT
form_NN
,_,
content_NN
after_IN
15_CD
December_NN
2003_CD
._.
Adoption_NOMZ
for_PIN
all_QUAN
and_CC
location_NOMZ
of_PIN
those_DEMO
disclosures_NN
._.
The_DT
other_JJ
entities_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
for_PIN
periods_NN
ending_VBG [WZPRES]
transition_NOMZ
guidance_NN
and_CC
annual_JJ
disclosure_NN
on_PIN
or_CC
after_IN
15_CD
March_NN
2004_CD
._.
FIN46R_CD
has_VPRT
not_XX0
,_,
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
148_CD
are_VPRT [BEMA]
effective_PRED
for_PIN
and_CC
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
,_,
a_DT
material_NN
effect_NN
fiscal_JJ
years_NN
ending_VBG [WZPRES]
after_IN
15_CD
December_NN
2002_CD
._.
on_PIN
the_DT
results_NN
or_CC
net_JJ
assets_NN
of_PIN
AstraZeneca_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
not_XX0
adopted_VBN
the_DT
fair_JJ
value_NN
based_VBN
method_NN
of_PIN
accounting_GER
for_PIN
stockSFAS_NN
No._NN
._.
132_CD
Revised_VBN
2003_CD
Employers_NN
based_VBN
employee_NN
compensation_NOMZ
and_CC
,_,
Disclosures_NN
about_IN
Pensions_NN
and_CC
Other_JJ
Posttherefore_NN
,_,
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
the_DT
transition_NOMZ
Retirement_NOMZ
Benefits_NN
was_VBD [PASS]
issued_VBN
on_PIN
23_CD
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
December_NN
2003_CD
and_CC
is_VPRT [BEMA]
effective_PRED
,_,
subject_JJ
to_PIN
certain_JJ
exemptions_NOMZ
,_,
for_PIN
fiscal_JJ
years_NN
ending_VBG [WZPRES]
on_PIN
SFAS_NN
No._NN
._.
149_CD
Amendment_NOMZ
of_PIN
Statement_NOMZ
or_CC
after_IN
15_CD
December_NN
2003_CD
._.
AstraZeneca_NN
133_CD
on_PIN
Derivative_JJ
Instruments_NOMZ
and_PHC
Hedging_GER
has_VPRT [PEAS]
complied_VBN
with_PIN
the_DT
new_JJ
requirements_NOMZ
in_PIN
Activities_NOMZ
that_TSUB
was_VBD [PASS]
issued_VBN
on_PIN
30_CD
April_NN
2003_CD
,_,
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
amends_NN
and_CC
clarifies_VPRT
accounting_GER
for_PIN
certain_JJ
Information_NOMZ
._.
derivative_JJ
instruments_NOMZ
particularly_RB
contracts_NN
with_PIN
certain_JJ
embedded_VBN
derivative_NN
instruments_NOMZ
and_CC
hedging_VBG
activities_NOMZ
under_IN
SFAS_NN
No._NN
._.
133_CD
Accounting_GER
for_PIN
Derivative_JJ
Instruments_NOMZ
and_PHC
Hedging_GER
Activities_NOMZ
._.
Except_PIN
where_RB
its_PIT
provisions_NN
clarify_VPRT
SFAS_NN
No._NN
._.
133_CD
implementation_NOMZ
issues_NN
previously_TIME
effective_JJ
,_,
the_DT
standard_JJ
applies_VPRT
prospectively_RB
for_PIN
contracts_NN
entered_VBN [WZPAST]
into_PIN [STPR]
,_,
and_ANDC
hedging_VBG
activities_NOMZ
designated_VBN
after_IN
,_,
30_CD
June_NN
2003_CD
._.
149_CD
did_VBD
not_XX0
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
results_NN
or_CC
net_JJ
assets_NN
of_PIN
AstraZeneca_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
116_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Net_JJ
income_NN
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
significant_JJ
difference_NN
between_PIN
the_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
treatment_NOMZ
of_PIN
the_DT
combination_NOMZ
of_PIN
Astra_NN
and_PHC
Zeneca_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
,_,
and_ANDC
in_PIN
the_DT
results_NN
of_PIN
preceding_VBG
periods_NN
,_,
condensed_JJ
statements_NOMZ
of_PIN
operations_NOMZ
and_PHC
cash_NN
flow_NN
under_IN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
the_DT
benefit_NN
of_PIN
US_FPP1
investors_NN
._.
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
equity_NOMZ
which_WDT [WHSUB]
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
income_NN
before_IN
exceptional_JJ
items_NN
3,036_CD
3,186_CD
3,044_CD
Exceptional_JJ
items_NN
after_IN
tax_NN
350_CD
138_CD
Net_JJ
income_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
3,036_CD
2,836_CD
2,906_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Amortisation_NOMZ
and_CC
other_JJ
acquisition_NOMZ
adjustments_NOMZ
952_CD
864_CD
1,514_CD
Others_NN
59_CD
55_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
17_CD
46_CD
57_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
values_NN
of_PIN
Astra_NN
266 239 249_CD
Others_NN
91_CD
99_CD
198_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
benefits_NN
expense_NN
43_CD
46_CD
29_CD
Software_NN
costs_NN
18_CD
46_CD
10_CD
Restructuring_GER
costs_NN
22_CD
Share_NN
based_VBN
compensation_NOMZ
12_CD
33_CD
7_CD
Fair_NN
value_NN
of_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
10_CD
93_CD
18_CD
Deferred_JJ
income_NN
recognition_NOMZ
14_CD
61_CD
75_CD
Unrealised_JJ
losses_NN
on_PIN
foreign_JJ
exchange_NN
and_PHC
others_NN
18_CD
1_CD
10_CD
Net_JJ
income_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
2,268_CD
2,307_CD
1,365_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
,_,
net_NN
of_PIN
tax_NN
,_,
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
133_CD
32_CD
Net_JJ
income_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
2,268_CD
2,307_CD
1,397_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
117_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
US_FPP1
GAAP_NN
Condensed_NN
Consolidated_NN
Statement_NOMZ
of_PIN
Operations_NOMZ
2003 2002 2001_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
18,849_CD
17,841_CD
16,222_CD
Cost_NN
of_PIN
sales_NN
4,469_CD
4,520_CD
4,198_CD
Distribution_NOMZ
costs_NN
162 141 122_CD
Research_NN
and_PHC
development_NOMZ
3,451_CD
3,069_CD
2,687_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
6,941_CD
6,165_CD
5,219_CD
Acquisition_NOMZ
related_VBN
costs_NN
224_CD
Amortisation_NOMZ
of_PIN
intangibles_NN
and_PHC
goodwill_NN
881_CD
1,052_CD
1,769_CD
Other_JJ
income_NN
225 308 283_CD
Operating_GER
income_NN
3,170_CD
3,202_CD
2,286_CD
Net_JJ
interest_NN
income_NN
63 140 188_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
taxation_NOMZ
3,233_CD
3,342_CD
2,474_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
965_CD
1,035_CD
1,109_CD
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
2,268_CD
2,307_CD
1,365_CD
Net_JJ
income_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
2,268_CD
2,307_CD
1,365_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
133_CD
32_CD
Net_JJ
income_NN
for_PIN
the_DT
year_NN
2,268_CD
2,307_CD
1,397_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
1,709_CD
1,733_CD
1,758_CD
Dilutive_JJ
impact_NN
of_PIN
share_NN
options_NOMZ
outstanding_JJ
millions_NN
3_CD
23_CD
Diluted_NN
weighted_JJ
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
millions_NN
1,712_CD
1,735_CD
1,761_CD
Net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
before_IN
change_NN
in_PIN
accounting_GER
policy_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
1.33_CD
$_$
1.33_CD
$_$
0.77_CD
Net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
after_IN
change_NN
in_PIN
accounting_GER
policy_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
1.33_CD
$_$
1.33_CD
$_$
0.79_CD
US_FPP1
GAAP_NN
Statement_NOMZ
of_PIN
Comprehensive_NN
Income_NN
2003 2002 2001_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
for_PIN
the_DT
year_NN
2,268_CD
2,307_CD
1,397_CD
Exchange_NN
gains_NN
losses_NN
net_NN
of_PIN
tax_NN
3,635_CD
2,919_CD
1,473_CD
Other_JJ
movements_NOMZ
,_,
net_NN
of_PIN
tax_NN
100_CD
73_CD
Total_JJ
Comprehensive_NN
Income_NN
5,803_CD
5,153_CD
76_CD
Other_JJ
movements_NOMZ
in_PIN
2003_CD
include_VPRT
the_DT
recognition_NOMZ
of_PIN
a_DT
minimum_JJ
liability_NOMZ
under_IN
SFAS_NN
No._NN
._.
87_CD
Employers_NN
Accounting_GER
for_PIN
Pensions_NN
of_PIN
$_$
177m_CD
._.
Tax_NN
effects_NN
on_PIN
exchange_NN
gains_NN
losses_NN
were_VBD
$_$
297_CD
m_NN
and_CC
on_PIN
other_JJ
movements_NOMZ
$_$
67m_CD
._.
The_DT
cumulative_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
net_NN
of_PIN
tax_NN
on_PIN
the_DT
translation_NOMZ
of_PIN
foreign_JJ
currency_NN
financial_JJ
statements_NOMZ
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
following_JJ
note_NN
:_:
2003 2002 2001_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
at_PIN
1_CD
January_NN
1,399_CD
4,318_CD
2,845_CD
Movement_NOMZ
in_PIN
year_NN
3,635_CD
2,919_CD
1,473_CD
Balance_NN
at_PIN
31_CD
December_NN
2,236_CD
1,399_CD
4,318_CD
The_DT
cumulative_JJ
other_JJ
movements_NOMZ
net_NN
of_PIN
tax_NN
at_PIN
31_CD
December_NN
2003_CD
was_VBD [BEMA]
a_DT
charge_NN
of_PIN
$_$
154m_CD
2002_CD
$_$
73m_CD
,_,
2001_CD
$_$
nil_JJ
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
118_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Stock_NN
compensation_NOMZ
In_PIN
the_DT
Groups_NN
Financial_NN
Statements_NOMZ
prepared_VBD
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
cost_NN
is_VPRT [PASS]
accrued_VBN
for_PIN
the_DT
share_NN
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
employees_NN
under_IN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
,_,
and_ANDC
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
as_IN
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
cost_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
difference_NN
between_PIN
the_DT
option_NOMZ
price_NN
and_CC
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
or_CC
,_,
for_PIN
variable_JJ
plans_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
the_DT
reporting_GER
period_NN
until_IN
measurement_NOMZ
date_NN
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
25_CD
any_QUAN
compensation_NOMZ
cost_NN
would_PRMD
be_VB [PASS]
amortised_VBN
over_IN
the_DT
period_NN
from_PIN
the_DT
date_NN
the_DT
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
the_DT
date_NN
they_TPP3
are_VPRT [BEMA]
first_JJ
exercisable_JJ
._.
Under_IN
US_FPP1
GAAP_NN
in_PIN
the_DT
net_JJ
income_NN
reconciliation_NOMZ
,_,
the_DT
Group_NN
has_VPRT [PEAS]
adjusted_VBN
for_PIN
stock_NN
compensation_NOMZ
costs_NN
as_IN
calculated_VBN [PRIV]
under_IN
APB_NN
Opinion_NN
No._NN
._.
123_CD
Accounting_GER
for_PIN
Stock-Based_NN
Compensation_NOMZ
sets_VPRT
out_PIN
an_DT
alternative_JJ
methodology_NN
for_PIN
recognizing_VBG [PRIV]
the_DT
compensation_NOMZ
cost_NN
based_VBN [WZPAST]
on_PIN
the_DT
fair_JJ
value_NN
at_PIN
grant_NN
date_NN
._.
Had_VBD
the_DT
Group_NN
adopted_VBD
this_DEMO
methodology_NN
,_,
the_DT
incremental_JJ
effect_NN
on_PIN
net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
as_IN
reported_VBN [PUBV]
2,268_CD
2,307_CD
1,397_CD
Compensation_NOMZ
cost_NN
under_IN
APB_NN
No._NN
._.
25_CD
12_CD
33_CD
7_CD
Compensation_NOMZ
cost_NN
under_IN
SFAS_NN
No._NN
._.
123 154 122_CD
83_CD
Pro_PIN
forma_FW
net_JJ
income_NN
2,126_CD
2,152_CD
1,321_CD
Pro_PIN
forma_FW
net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_CC
diluted_VBN
:_:
As_IN
reported_VBN [PUBV]
$_$
1.33_CD
$_$
1.33_CD
$_$
0.79_CD
Pro_PIN
forma_FW
$_$
1.24_CD
$_$
1.24_CD
$_$
0.75_CD
The_DT
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
is_VPRT [PASS]
estimated_VBN [PRIV]
,_,
based_VBN [PASTP]
on_PIN
the_DT
stock_NN
price_NN
at_PIN
the_DT
grant_NN
date_NN
,_,
using_VBG [PRESP]
the_DT
Black-Scholes_NN
option_NOMZ
pricing_GER
model_NN
with_PIN
the_DT
following_VBG
assumptions_NOMZ
:_:
2003 2002 2001_CD
Dividend_NN
yield_NN
2.0_CD
%_NN
1.6_CD
%_NN
1.5_CD
%_NN
Expected_VBN [PRIV]
volatility_NOMZ
25.0_CD
%_NN
30.0_CD
%_NN
20.0_CD
%_NN
Risk-free_JJ
interest_NN
rate_NN
4.3_CD
%_NN
5.2_CD
%_NN
4.2_CD
%_NN
Expected_VBN [PRIV]
lives_NN
:_:
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
6.0_CD
years_NN
6.0_CD
years_NN
6.0_CD
years_NN
Expected_VBN [PRIV]
lives_NN
:_:
SAYE_NN
Plan_NN
4.3_CD
years_NN
4.3_CD
years_NN
4.3_CD
years_NN
In_PIN
the_DT
initial_JJ
phase-in_PIN
period_NN
,_,
the_DT
effects_NN
of_PIN
applying_VBG
SFAS_NN
No._NN
._.
123_CD
for_PIN
disclosing_VBG [PUBV]
compensation_NOMZ
cost_NN
may_POMD
not_XX0
be_VB
representative_NN
of_PIN
the_DT
effects_NN
on_PIN
pro_PIN
forma_FW
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
for_PIN
future_JJ
years_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
119_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
,_,
the_DT
pension_NN
costs_NN
of_PIN
the_DT
major_JJ
UK_NN
retirement_NOMZ
plan_NN
and_CC
of_PIN
the_DT
retirement_NOMZ
plans_NN
of_PIN
the_DT
major_JJ
non-UK_JJ
subsidiaries_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
132_CD
._.
These_DEMO
plans_NN
comprise_VPRT
a_DT
substantial_JJ
portion_NOMZ
of_PIN
the_DT
actuarial_JJ
liabilities_NOMZ
of_PIN
all_QUAN
AstraZeneca_NN
retirement_NOMZ
plans_NN
._.
The_DT
changes_NN
in_PIN
projected_VBN
benefit_NN
obligations_NOMZ
,_,
plan_NN
assets_NN
and_PHC
details_NN
of_PIN
the_DT
funded_JJ
status_NN
of_PIN
these_DEMO
retirement_NOMZ
plans_NN
,_,
together_RB
with_PIN
the_DT
changes_NN
in_PIN
the_DT
accumulated_VBN
other_JJ
post-retirement_JJ
benefit_NN
obligations_NOMZ
,_,
under_IN
SFAS_NN
132are_CD
as_IN
follows_VPRT
:_:
Other_JJ
Pension_NN
post-retirement_NOMZ
benefits_NN
benefits_NN
Change_NN
in_PIN
projected_VBN
benefit_NN
obligation_NOMZ
2003 2002 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
5,026_CD
4,337_CD
210_CD
205_CD
Service_NN
cost_NN
123_CD
114_CD
9_CD
8_CD
Interest_NN
cost_NN
290_CD
263_CD
14_CD
14_CD
Participant_NN
contributions_NOMZ
22_CD
18_CD
1_CD
Actuarial_JJ
loss_NN
508_CD
80_CD
24_CD
23_CD
Special_JJ
termination_NOMZ
benefits_NN
12_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
4_CD
24_CD
Benefits_NN
paid_VBN
226_CD
206_CD
19_CD
19_CD
Exchange_NN
495_CD
408_CD
3_CD
3_CD
Benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
6,242_CD
5,026_CD
242_CD
210_CD
Other_JJ
Pension_NN
post-retirement_NOMZ
benefits_NN
benefits_NN
Change_NN
in_PIN
plan_NN
assets_NN
2003 2002 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Fair_NN
value_NN
at_PIN
beginning_GER
of_PIN
year_NN
4,038_CD
3,753_CD
133_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
551_CD
142_CD
35_CD
16_CD
Group_NN
contribution_NOMZ
383_CD
284_CD
43_CD
161_CD
Participant_NN
contributions_NOMZ
22_CD
18_CD
1_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
Benefits_NN
paid_VBD
226_CD
206_CD
17_CD
12_CD
Exchange_NN
406_CD
331_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
5,174_CD
4,038_CD
195_CD
133_CD
Funded_VBN
status_NN
of_PIN
plans_NN
1,068_CD
988_CD
47_CD
77_CD
Unrecognised_JJ
net_JJ
loss_NN
1,220_CD
938_CD
65_CD
Prior_RB
service_NN
cost_NN
not_XX0
recognized_VBN [PRIV]
35_CD
29_CD
9_CD
Unrecognised_JJ
net_JJ
obligation_NOMZ
on_PIN
implementation_NOMZ
3_CD
187_CD
18_CD
9_CD
77_CD
Adjustments_NOMZ
to_TO
recognize_VB [PRIV]
minimum_JJ
liability_NOMZ
:_:
Intangible_JJ
assets_NN
39_CD
45_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
221_CD
45_CD
Accrued_VBN
benefit_NN
asset_NN
liability_NOMZ
73_CD
108_CD
9_CD
77_CD
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
projected_VBN
benefit_NN
obligation_NOMZ
,_,
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
the_DT
plan_NN
assets_NN
in_PIN
respect_NN
of_PIN
the_DT
pension_NN
plans_NN
above_PLACE
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
were_VBD
$_$
5,287_CD
m_NN
,_,
$_$
4,524_CD
m_NN
and_CC
$_$
4,249_CD
m_NN
,_,
2002_CD
$_$
4,249_CD
m_NN
,_,
$_$
3,557_CD
m_NN
and_CC
$_$
3,296_CD
m_NN
respectively_RB
._.
The_DT
total_JJ
accumulated_VBN
benefit_NN
obligations_NOMZ
for_PIN
the_DT
pension_NN
plans_NN
was_VBD
$_$
5,318_CD
m_NN [BEMA]
2002_CD
$_$
4,214_CD
m._FW
The_DT
measurement_NOMZ
date_NN
for_PIN
the_DT
plan_NN
assets_NN
and_PHC
benefit_NN
obligations_NOMZ
set_VBN [WZPAST]
out_PIN
above_PLACE
was_VBD [BEMA]
31_CD
December_NN
2003_CD
._.
Contributions_NOMZ
to_PIN
the_DT
plans_NN
in_PIN
2004_CD
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB
$_$
111m_CD
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
120_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Assumed_JJ
discount_NN
rates_NN
and_PHC
rates_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
projected_VBN
benefit_NN
obligations_NOMZ
together_RB
with_PIN
long_JJ
term_NN
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
vary_VPRT
according_VBG
to_PIN
the_DT
economic_JJ
conditions_NOMZ
of_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
retirement_NOMZ
plans_NN
are_VPRT [PASS]
situated_VBN
._.
The_DT
weighted_JJ
average_NN
rates_NN
used_VBN [WZPAST]
for_PIN
calculation_NOMZ
of_PIN
year_NN
end_NN
benefit_NN
obligations_NOMZ
and_PHC
forecast_NN
benefit_NN
cost_NN
in_PIN
the_DT
main_JJ
retirement_NOMZ
plans_NN
and_CC
other_JJ
benefit_NN
obligations_NOMZ
for_PIN
SFAS_NN
132_CD
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2003 2002 2001 2003_CD
2002_CD
2001_CD
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
Discount_NN
rate_NN
5.5_CD
5.8_CD
6.0_CD
5.9_CD
6.6_CD
7.1_CD
Long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
4.0_CD
4.1_CD
4.4_CD
5.0_CD
4.8_CD
n_NN
a_DT
Expected_VBN [PRIV]
long_JJ
term_NN
return_NN
on_PIN
assets_NN
6.6_CD
6.4_CD
6.5_CD
7.8_CD
7.8_CD
n_NN
a_DT
The_DT
Group_NN
has_VPRT [PEAS]
assumed_VBN [PRIV]
a_DT
long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
healthcare_NN
costs_NN
of_PIN
10_CD
%_NN
,_,
reducing_VBG [PRESP]
to_PIN
5_CD
%_NN
._.
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2003 2002 2001 2003_CD
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
periodic_JJ
cost_NN
Service_NN
cost_NN
present_JJ
value_NN
of_PIN
benefits_NN
accruing_VBG [WZPRES]
during_PIN
the_DT
year_NN
123 114 102_CD
9_CD
87_CD
Interest_NN
cost_NN
on_PIN
projected_VBN
benefit_NN
obligations_NOMZ
290 263 243_CD
14_CD
14_CD
14_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
280 263 242_CD
14_CD
Net_JJ
amortisation_NOMZ
and_CC
deferral_JJ
34_CD
28_CD
39_CD
2_CD
1_CD
2_CD
Net_JJ
periodic_JJ
cost_NN
for_PIN
the_DT
year_NN
167 142 142_CD
11_CD
21_CD
19_CD
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
a_DT
one_CD
percentage_NN
point_NN
change_NN
in_PIN
the_DT
weighted_JJ
average_JJ
healthcare_NN
costs_NN
trend_NN
would_PRMD
have_VB
the_DT
following_JJ
effects_NN
on_PIN
the_DT
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
net_JJ
periodic_JJ
cost_NN
at_PIN
31_CD
December_NN
2003_CD
:_:
One_CD
percentage_NN
point_NN
Increase_VPRT
Decrease_NN
$_$
m_CD
$_$
m_CD [PASS]
Accumulated_VBN
benefit_NN
obligation_NOMZ
13_CD
11_CD
Net_JJ
periodic_JJ
cost_NN
2_CD
2_CD
The_DT
weighted_JJ
average_JJ
allocation_NOMZ
of_PIN
pension_NN
and_CC
other_JJ
post-retirement_JJ
plan_NN
assets_NN
was_VBD
as_IN
follows_VPRT
:_:
2003_CD
2002_CD
%_NN
%_NN
Equities_NOMZ
49.2_CD
40.6_CD
Bonds_NN
48.8_CD
56.5_CD
Other_JJ
2.0_CD
2.9_CD
The_DT
benefits_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
the_DT
future_NN
are_VPRT
as_IN
follows_VPRT
:_:
$_$
m_CD [BEMA]
2004 267 2005 275_CD
2006 284 2007 293_CD
2008 302 2009 2013_CD
1,695_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
121_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Taxation_NOMZ
2003 2002 2001_CD
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
UK_NN
taxation_NOMZ
Corporation_NOMZ
tax_NN
138 165 147_CD
Double_RB
taxation_NOMZ
relief_NN
23_CD
7_CD
4_CD
Deferred_VBN
taxation_NOMZ
88_CD
40_CD
10_CD
Overseas_PLACE
taxation_NOMZ
Overseas_PLACE
taxes_NN
878 921 831_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
35_CD
51_CD
30_CD
Deferred_JJ
taxation_NOMZ
151_CD
33_CD
95_CD
Share_NN
of_PIN
taxation_NOMZ
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
965_CD
1,035_CD
1,109_CD
The_DT
table_NN
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
to_PIN
the_DT
Groups_NN
actual_JJ
charge_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
2003 2002 2001_CD
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Income_NN
on_PIN
continuing_VBG
operations_NOMZ
3,233_CD
3,342_CD
2,506_CD
Taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
for_PIN
2003_CD
30_CD
%_NN
for_PIN
2002_CD
,_,
30_CD
%_NN
for_PIN
2001_CD
970_CD
1,002_CD
751_CD
Differences_NN
in_PIN
effective_JJ
overseas_PLACE
tax_NN
rates_NN
41_CD
648_CD
Items_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
89_CD
83_CD
352_CD
Items_NN
not_XX0
chargeable_JJ
for_PIN
tax_NN
purposes_NN
88_CD
110_CD
76_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
35_CD
51_CD
30_CD
Exceptional_JJ
items_NN
105_CD
4_CD
Tax_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
965_CD
1,035_CD
1,109_CD
In_PIN
2003_CD
,_,
claims_VPRT [PUBV]
amounting_VBG
to_TO
$_$
95m_CD
2002_CD
$_$
43m_CD
for_PIN
tax_NN
relief_NN
arising_VBG [WZPRES]
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
restructuring_GER
of_PIN
the_DT
AMI_NN
joint_JJ
venture_NN
in_PIN
1998_CD
were_VBD [PASS]
made_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
reliefs_NN
are_VPRT [PASS]
adjusted_VBN
against_PIN
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
restructuring_GER
and_CC
included_VBD
in_PIN
other_JJ
adjustments_NOMZ
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
122_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Shareholders_NN
equity_NOMZ
2003_CD
2002_CD
$_$
m_CD
$_$
m_CD [BEMA]
Total_JJ
shareholders_NN
equity_NOMZ
under_IN
UK_NN
GAAP_NN
13,178_CD
11,172_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Goodwill_NN
14,311_CD
12,692_CD
Tangible_JJ
and_PHC
intangible_JJ
fixed_VBN
assets_NN
7,661_CD
7,707_CD
Others_NN
145_CD
86_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
255_CD
238_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
value_NN
of_PIN
Astra_NN
2,313_CD
2,305_CD
Others_NN
207_CD
159_CD
Dividend_NN
914_CD
808_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
benefits_NN
expense_NN
534_CD
295_CD
Software_NN
costs_NN
capitalized_JJ
46_CD
64_CD
Fair_NN
value_NN
of_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
109_CD
99_CD
Deferred_JJ
income_NN
recognition_NOMZ
14_CD
Others_NN
89_CD
90_CD
Shareholders_NN
equity_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
33,654_CD
30,183_CD
Acquired_VBN
intangible_JJ
assets_NN
Details_NN
of_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
intangible_JJ
fixed_JJ
assets_NN
and_CC
past_JJ
and_CC
projected_VBD
amortisation_NOMZ
expenses_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
2003_CD
2002_CD
Gross_NN
Gross_NN
carrying_VBG [WZPRES]
Accumulated_NN
carrying_VBG [WZPRES]
Accumulated_NN
amount_NN
amortisation_NOMZ
amount_NN
amortisation_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Product_NN
rights_NN
13,733_CD
5,274_CD
12,058_CD
3,672_CD
Marketing_GER
and_PHC
distribution_NOMZ
rights_NN
1,659_CD
831_CD
1,513_CD
600_CD
Software_NN
462 305 354 241_CD
Others_NN
421 329 408 294_CD
Total_JJ
16,275_CD
6,739_CD
14,333_CD
4,807_CD
Aggregate_NN
amortisation_NOMZ
expense_NN
$_$
m_CD [BEMA]
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2003_CD
1,245_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2002_CD
1,154_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2001_CD
1,135_CD
Estimated_VBN [PRIV]
amortisation_NOMZ
expense_NN
$_$
m_CD [BEMA]
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1,228_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2005_CD
1,228_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2006_CD
1,216_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2007_CD
1,128_CD
For_PIN
year_NN
ended_VBD
31_CD
December_NN
2008_CD
1,128_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
Additional_JJ
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
for_PIN
US_FPP1
Investors_NN
123_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
weighted_JJ
average_JJ
amortisation_NOMZ
period_NN
in_PIN
respect_NN
of_PIN
each_QUAN
class_NN
of_PIN
intangible_JJ
asset_NN
is_VPRT
as_IN
follows_VPRT
:_:
Product_NN
rights_NN
13_CD
years_NN
Marketing_GER
and_PHC
distribution_NOMZ
rights_NN
16_CD
years_NN
Software_NN
4_CD
years_NN
Other_JJ
8_CD
years_NN
Goodwill_NN
The_DT
changes_NN
in_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
goodwill_NN
for_PIN
the_DT
two_CD
years_NN
ended_VBN
31_CD
December_NN
2003_CD
were_VBD
as_IN
follows_VPRT
:_:
$_$
m_CD
Balance_NN
as_IN
at_PIN
1_CD
January_NN
2002_CD
11,943_CD
Acquired_VBN
62_CD
Reclassification_NOMZ
of_PIN
assembled_VBN
workforce_NN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
141_CD
364_CD
Exchange_NN
adjustments_NOMZ
1,278_CD
Balance_NN
as_IN
at_PIN
1_CD
January_NN
2003_CD
13,647_CD
Acquired_VBN
1_CD
Exchange_NN
adjustments_NOMZ
1,658_CD
Balance_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
15,306_CD
Adoption_NOMZ
of_PIN
SFAS_NN
142_CD
in_PIN
2002_CD
resulted_VBD
in_PIN
the_DT
cessation_NOMZ
of_PIN
amortisation_NOMZ
of_PIN
goodwill_NN
._.
Had_VBD
goodwill_NN
not_XX0
been_VBN [PASS]
amortised_VBN
in_PIN
2001_CD
,_,
net_JJ
income_NN
would_PRMD
have_VB [PEAS]
increased_VBN
from_PIN
$_$
1,397_CD
m_NN
to_TO
$_$
2,125_CD
m_NN [BEMA]
with_PIN
a_DT
corresponding_JJ
increase_NN
in_PIN
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
from_PIN
$_$
0.77_CD
to_TO
$_$
1.21_CD
._.
US_FPP1
GAAP_NN
Condensed_NN
Consolidated_NN
Statement_NOMZ
of_PIN
Cash_NN
Flows_NN
2003 2002 2001_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
3,416_CD
4,833_CD
3,126_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
771 806 260_CD
New_NN
fixed_JJ
asset_NN
investments_NOMZ
120_CD
1_CD
5_CD
Disposal_NN
of_PIN
fixed_JJ
assets_NN
38_CD
66_CD
44_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
80_CD
44_CD
Capital_NN
expenditure_NN
1,515_CD
1,608_CD
1,582_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
investing_VBG
activities_NOMZ
746_CD
2,349_CD
1,327_CD
Net_JJ
cash_NN
flow_NN
before_IN
financing_VBG
2,670_CD
2,484_CD
1,799_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Equity_NOMZ
dividends_NN
paid_VBD
1,222_CD
1,234_CD
1,236_CD
Re-purchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
1,107_CD
1,154_CD
994_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
short_JJ
term_NN
borrowings_GER
13_CD
7_CD
Loans_NN
repaid_VBN
new_JJ
loans_NN
345_CD
105_CD
28_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
financing_VBG
activities_NOMZ
2,674_CD
2,506_CD
2,195_CD
Decrease_NN
in_PIN
cash_NN
4_CD
22_CD
396_CD
Cash_NN
:_:
At_PIN
1_CD
January_NN
524 510 908_CD
Decrease_NN
in_PIN
cash_NN
4_CD
22_CD
396_CD
Exchange_NN
movements_NOMZ
61_CD
36_CD
2_CD
At_PIN
31_CD
December_NN
581 524 510_CD
Interest_NN
paid_VBN [WZPAST]
was_VBD
$_$
32m_CD
in_PIN
2003_CD
,_,
$_$
96m_CD
in_PIN
2002_CD
and_CC
$_$
84m_CD
in_PIN
2001_CD
._.
